Lung Cancer Therapeutics Market

1

• The targeted segment is forecast to emerge
  dominant among various therapies in the global
  lung cancer therapeutics market, finds Fortune
  Business Insights in a new study. The study is
  titled Lung Cancer Therapeutics Market Global
  Market Analysis, Insights, and Forecasts, 2018
  2026. According to the study, the global lung
  cancer therapeutics market will exhibit an
  exponential CAGR of 13.0 to reach a value of
  US 48,725.9 Mn by 2026 from US 18,327.6 Mn in
  2018.
• Lung cancer is considered one of the leading
  causes of death by cancer. Cancer can be a result
  of continuous exposure to asbestos, and
  unhealthy lifestyle that includes habits such as
  pipe smoking, cigarette smoking, cigar smoking.
  The rising incidence of lung cancer is
  subsequently fuelling demand for various
  therapies in the global lung cancer therapeutics
  market.
• Get Sample PDF Brochure https//www.fortunebusin
  essinsights.com/enquiry/request-sample-pdf/lung-ca
  ncer- therapeutics-market-100473
• Key Players
• Astellas Pharma US
• Celgene
• Merck Sharp Dohme GmbH
• Pfizer
• Eli Lilly and Company
• Bristol-Myers Squibb
• AstraZeneca
• Boehringer Ingelheim Pharmaceutical, Takeda
• Novartis
• Sanofi.

2
nations. Besides this, increasing investment by
market players in research and development
activities to discover novel therapeutics is
driving the global market. On the flip side,
most of the anticipated drugs for lung cancer are
still in their early testing stage and might
take some time before finally getting launched in
the market. This gestation gap between clinical
trial and final launch might create uncertainty
among players, making them skeptical about
further investments in lung cancer treatment
researches. This may hamper the market growth
during the forecast period. Furthermore, Cure
for a certain type of cancer is yet to be
discovered. The cure is yet to be discovered as
targeted therapies have no effect on such cancer
types. This is more likely to create challenges
for the global market for lung cancer
therapeutics during the forecast period. The
Asia Pacific to Emerge as the Fastest Growing
Region with Rising in Cancer Awareness
Programs North America is expected to dominate
the global market for lung cancer therapeutics.
In 2018 the region generated a revenue of US
8,093.2 Mn. Growth in this region is attributable
to the rising prevalence and diagnostics of lung
cancer and the increasing adoption of advanced
lung cancer therapeutics. Besides this,
increasing awareness about cancer is enabling
the market in Asia Pacific exhibit a faster
CAGR. A few novel therapeutics are introduced in
the market, impelling leading players to research
on improved medication. For instance, Genentech,
a company operating in the lung cancer
therapeutics market has recently launched their
new drug named, Alecensa (alectinib), in order
to treat ALK-positive non-small cell lung cancer.
Such strategies adopted by players will bode
well for the global lung cancer therapeutics
market in the long run. Browse Complete Report
Details https//www.fortunebusinessinsights.com/i
ndustry-reports/lung-cancer-therapeutics-market-
100473 About Us Fortune Business Insights
offers expert corporate analysis and accurate
data, helping organizations of all sizes make
timely decisions. We tailor innovative solutions
for our clients, assisting them to address
challenges distinct to their businesses. Our goal
is to empower our clients with holistic market
intelligence, giving a granular overview of the
market they are operating in. Our reports
contain a unique mix of tangible insights and
qualitative analysis to help companies achieve
sustainable growth. Our team of experienced
analysts and consultants use industry-leading
research tools and techniques to compile
comprehensive market studies, interspersed with
relevant data.
3
At Fortune Business Insights we aim at
highlighting the most lucrative growth
opportunities for our clients. We, therefore,
offer recommendations, making it easier for them
to navigate through technological and
market-related changes. Our consulting services
are designed to help organizations identify
hidden opportunities and understand prevailing
competitive challenges. Contact Us Fortune
Business Insights Pvt. Ltd. 308, Supreme
Headquarters, Survey No. 36, Baner, Pune-Bangalor
e Highway, Pune - 411045, Maharashtra,
India. Phone US 1 424 253 0390 UK 44 2071
939123 APAC 91 744 740 1245 Email
sales_at_fortunebusinessinsights.com